Showing results (1-10 of 894) with videos related to
Sort By:
Pageof 90
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Acute Myeloid Leukemia: Past, Present, and Prospects for the FutureNicholas J Short, Farhad RavandiHaematologica|July 6, 2019
How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?Nicholas J Short, Farhad RavandiExpert Review of Hematology|May 10, 2016
The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical reviewNicholas J Short, Farhad RavandiBlood Cancer Journal|September 11, 2023
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitorsNicholas J Short, Daniel Nguyen, Farhad RavandiBest Practice & Research. Clinical Haematology|October 21, 2017
Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?Nicholas J Short, Hagop Kantarjian, Elias Jabbour, et al.Current Hematologic Malignancy Reports|February 10, 2018
Novel Therapies for Older Adults With Acute Lymphoblastic LeukemiaNicholas J Short, Hagop Kantarjian, Elias Jabbour, et al.Therapeutic Advances in Hematology|February 26, 2019
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemiaNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.Current Treatment Options in Oncology|January 25, 2019
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaIman Abou Dalle, Elias Jabbour, Nicholas J Short, et al.Journal of Hematology & Oncology|June 7, 2020
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directionsBachar Samra, Elias Jabbour, Farhad Ravandi, et al.Journal of Hematology & Oncology|September 4, 2021
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemiaMarisa J L Aitken, Farhad Ravandi, Keyur P Patel, et al.Pageof 90